U.S., April 18 -- ClinicalTrials.gov registry received information related to the study (NCT07537257) titled 'VEN+IDAC vs IDAC in AML' on April 03.
Brief Summary: This study intends to use a randomized controlled design to compare the MRD-negativw rate and related efficacy and safety of venetoclax combined with intermediate-dose cytarabine (IDAC) versus IDAC in the consolidation treatment of patients with AML after remission, providing high-quality evidence-based medical evidence for optimizing post-remission consolidation therapy for AML and improving patients' prognosis.
Study Start Date: April 01
Study Type: INTERVENTIONAL
Condition:
AML (Acute Myelogenous Leukemia)
Intervention:
DRUG: Ventoclax
Venetoclax 400mg per day from day ...